The researchers note that this finding is troubling since KD and CVD are independent risk factors leading to increased prevalence of KD in patients with CVD and vice versa.
A commentary discusses what widespread exclusion of patients with KD from cardiovascular trials mean for clinicians managing CVD in patients with KD? It highlights that the currently available RCT data on the efficacy and safety of cardiovascular interventions in patients with KD is insufficient to make recommendations on the optimal approach for many therapies. It notes that the number of RCTs within the field of nephrology is low, and the trials are of poor quality and are unlikely to provide adequate data on the treatment of CVD in patients with KD, whilst the extrapolation of trial results conducted in the general population to patients with KD may or may not be appropriate.